The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria

References

• García-Sanz R, Orfão A, González M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93(3):1032–1037.
   PubMed Web of Science ®Google Scholar
• Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(5):1044–1052.
   PubMed Web of Science ®Google Scholar
• Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev. 2011;25(3):107–112.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Lokhorst HM, Anderson KC, et al. How I treat plasma cell leukemia. Blood. 2012;120(12):2376–2389.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974;133(5):813–818.
   PubMedGoogle Scholar
• Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the international myeloma working group. Leukemia. 2013;27(4):780–791.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124(6):907–912.
   PubMed Web of Science ®Google Scholar
• An G, Qin X, Acharya C, et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol. 2015;94(2):257–264.
   PubMed Web of Science ®Google Scholar
• Granell M, Calvo X, Garcia-Guiñón A, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017;102(6):1099–1104.
   PubMed Web of Science ®Google Scholar
• Ravi P, Kumar SK, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018;8(12):116.
   PubMedGoogle Scholar
• Evans LA, Jevremovic D, Nandakumar B, et al. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. Am J Hematol. 2020;95(6):637–642.
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the international myeloma working group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192.
   PubMed Web of Science ®Google Scholar
• Royer B, Minvielle S, Diouf M, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the intergroupe francophone du Myélome. J Clin Oncol. 2016;34(18):2125–2132.
   PubMed Web of Science ®Google Scholar
• Nandakumar B, Kumar SK, Dispenzieri A, et al. Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy. Mayo Clin Proc. 2021;96(3):677–687.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Kryukov F, Rihova L, et al. Plasma cell leukemia: from biology to treatment. Eur J Haematol. 2015;95(1):16–26.
   PubMed Web of Science ®Google Scholar
• Paiva B, Paino T, Sayagues JM, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591–3598.
   PubMed Web of Science ®Google Scholar
• Garcés J-J, Simicek M, Vicari M, et al. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia. 2020;34(2):589–603.
   PubMed Web of Science ®Google Scholar
• Garcés J-J, Puig N, Termini R, et al. Circulating tumor cells (CTCs) in smoldering and active multiple myeloma (MM): mechanism of egression, clinical significance and therapeutic endpoints. Blood. 2021;138(Supplement 1):76–76.
   Google Scholar
• Lemieux C, Johnston LJ, Lowsky R, et al. Outcomes with autologous or allogeneic stem cell transplantation in patients with plasma cell leukemia in the era of novel agents. Biol Blood Marrow Transplant. 2020;26(12):e328–e332.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Kalaycio ME, Vela-Ojeda J, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the center for international blood and marrow transplant research. Leukemia. 2012;26(5):1091–1097.
   PubMed Web of Science ®Google Scholar
• Katodritou E, Terpos E, Delimpasi S, et al. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018;8(3):31.
   PubMedGoogle Scholar
• Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883–1898.
   PubMed Web of Science ®Google Scholar
• Tuazon SA, Holmberg LA, Nadeem O, et al. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021;11(2):23.
   PubMed Web of Science ®Google Scholar
• Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32(1):102–110.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Papadhimitriou SI, Terpos E, Liapis K, et al. The cytogenetic profile of primary and secondary plasma cell leukemia: etiopathogenetic perspectives, prognostic impact and clinical relevance to newly diagnosed multiple myeloma with differential circulating clonal plasma cells. Biomedicines. 2022;10(2):209.
   PubMed Web of Science ®Google Scholar
• Skerget S, Penaherrera D, Mikhael J, et al. High-risk gene expression subtype provides molecular basis for different clinical presentation of primary and secondary plasma cell leukemia. Blood. 2021;138(Supplement 1):726–726.
   Google Scholar
• Cazaubiel T, Leleu X, Perrot A, et al. Primary plasma cell leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature. Blood. 2022;139(17):2666–2672.
   PubMed Web of Science ®Google Scholar
• Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–2400.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Buadi FK, Kumar SK. Combination therapy incorporating bcl-2 inhibition with venetoclax for the treatment of refractory primary plasma cell leukemia with t(11;14). Eur J Haematol. 2018;100(2):215–217.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Mihalyova J, Kascak M, et al. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol. 2019;94(1):E35–e37.
   PubMed Web of Science ®Google Scholar
• Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol. 2020;95(2):E34–e35.
   PubMed Web of Science ®Google Scholar
• Roy T, An JB, Doucette K, et al. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression. Leuk Lymphoma. 2022;63(3):759–761.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35.
   PubMed Web of Science ®Google Scholar
• Yu T, Xu Y, An G, et al. Primary plasma cell leukemia: real-world retrospective study of 46 patients from a single-center study in China. Clin Lymphoma Myeloma Leuk. 2020;20(10):e652–e659.
   PubMed Web of Science ®Google Scholar